Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern (Q39824145)

14 September 2017

Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern (English)

1 reference

14 September 2017

0 references

Alehegn Gelaye

1

1 reference

14 September 2017

Abdallah Haidar

2

1 reference

14 September 2017

Christina Kassab

3

1 reference

14 September 2017

Syed Kazmi

4

1 reference

14 September 2017

Prabhat Sinha

5

1 reference

14 September 2017

21 March 2016

1 reference

Case reports in critical care

14 September 2017

1 reference

14 September 2017

2016

1 reference

14 September 2017

1656182

1 reference

Creative Commons Attribution 4.0 International

14 September 2017

start time

1 January 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

1 reference

April 2022 Public Data File from Crossref

cites work

Invokamet (Canagliflozin plus Metformin HCl): First Fixed-Dose Combination with an SGLT2 Inhibitor Approved for the Treatment of Patients with Type 2 Diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Canagliflozin: a sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes mellitus

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Toxic alcohol ingestions: clinical features, diagnosis, and management

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Treatment of the alcohol intoxications: ethylene glycol, methanol and isopropanol

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Anion and osmolal gaps in the diagnosis of methanol poisoning: clinical study in 28 patients

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4819091

Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors

20 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27088018

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1155/2016/1656182

1 reference

14 September 2017

1 reference

14 September 2017

1 reference